Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 4/20 | 0.41 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.41 |
| ▸ | TYMP | P19971 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 7/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.36 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3687661 | 1.00 | SLC6A11 (0.41) | SLC6A11SLC6A1TYMPKIF11KCNH2 | |
| SCHEMBL9908644 | 1.00 | SLC6A11 (0.41) | SLC6A11SLC6A1TYMPKIF11KCNH2 | |
| SCHEMBL26315910 | 1.00 | SLC6A11 (0.41) | SLC6A11SLC6A1TYMPKIF11KCNH2 | |
| SCHEMBL31589135 | 1.00 | SLC6A11 (0.41) | SLC6A11SLC6A1TYMPKIF11KCNH2 | |
| SCHEMBL19463682 | 0.89 | SLC6A11 (0.43) | SLC6A11SLC6A1TYMPKIF11KCNH2 | |
| SCHEMBL20414094 | 0.88 | SLC6A11 (0.43) | SLC6A11SLC6A1TYMPKIF11KCNH2 | |
| SCHEMBL6855480 | 0.83 | CHRNB4 (0.34) | SLC6A1ALK | |
| Hydroxyamine SCHEMBL8631065 | 0.81 | SLC6A2 (0.33) | ALK | |
| SCHEMBL6855484 | 0.81 | SLC6A2 (0.32) | ALK | |
| Hydroxyamine SCHEMBL8631067 | 0.79 | SLC6A2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745238-A1 | OLIGONUCLEOTIDE TARGETING ANGIOTENSINOGEN AND USE THEREOF | Anlong Biopharmaceutical Co., Ltd. (CN) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025264952-A2 | NOVEL RNA THERAPEUTICS AND USES THEREOF | ELI LILLY AND COMPANY (US) | 2025-12-26 | — | — | WO | disclosed |
| CN-119998450-A | Oligonucleotide targeting angiotensinogen and application thereof | 北京安龙生物医药有限公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119925624-A | Liver targeting compound and conjugate, preparation method and application thereof | 上海数因信科智能科技有限公司 | 2025-05-06 | — | — | CN | disclosed |
| WO-2025087442-A1 | OLIGONUCLEOTIDE TARGETING LIPOPROTEIN A AND USE THEREOF | 北京安龙生物医药有限公司 | 2025-05-01 | — | — | WO | disclosed |
| WO-2025077916-A1 | TRANSTHYRETIN-TARGETING OLIGONUCLEOTIDE AND USE THEREOF | 北京安龙生物医药有限公司 | 2025-04-17 | — | — | WO | disclosed |
| WO-2025021829-A1 | MULTIVALENT CARGO-CARRYING COMPLEXES AND USES THEREOF | ASTRAZENECA AB (SE) | 2025-01-30 | — | — | WO | disclosed |
| WO-2025016342-A1 | OLIGONUCLEOTIDE TARGETING ANGIOTENSINOGEN AND USE THEREOF | 北京安龙生物医药有限公司 | 2025-01-23 | — | — | WO | disclosed |
| CN-118993970-A | Preparation method of L96 side chain compound | 苏州富士莱医药股份有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118206597-A | GalNAc-siRNA conjugate structure and application thereof | 北京安龙生物医药有限公司 | 2024-06-18 | — | — | CN | disclosed |
| EP-1991705-A4 | COMPOUNDS AND METHODS FOR FLUORESCENT LABELING | EPOCH BIOSCIENCES INC (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1991705-A2 | COMPOUNDS AND METHODS FOR FLUORESCENT LABELING | Epoch Biosciences, Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| EP-1466176-A4 | COMPOUNDS AND METHODS FOR FLUORESCENT LABELING | EPOCH BIOSCIENCES INC (US) | 2008-10-01 | — | — | EP | disclosed |
| WO-2007098336-A2 | COMPOUNDS AND METHODS FOR FLUORESCENT LABELING | EPOCH BIOSCIENCES, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| US-20060204990-A1 | Compounds and methods for fluorescent labeling | EPOCH BIOSCIENCES, INC. (US) | 2006-09-14 | — | — | US | disclosed |
| US-20050277144-A1 | Compounds and methods for fluorescent labeling | EPOCH BIOSCIENCES, INC. (US) | 2005-12-15 | — | — | US | disclosed |
| US-6972339-B2 | Compounds and methods for fluorescent labeling | EPOCH BIOSCIENCES, INC. (US) | 2005-12-06 | — | — | US | disclosed |
| US-20050176066-A1 | Compounds and methods for fluorescent labeling | EPOCH BIOSCIENCES, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| EP-1466176-A2 | COMPOUNDS AND METHODS FOR FLUORESCENT LABELING | Epoch Biosciences, Inc. (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2003023357-A2 | COMPOUNDS AND METHODS FOR FLUORESCENT LABELING | EPOCH BIOSCIENCES, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176066-A1 | Compounds and methods for fluorescent labeling | HLCS, GLB1, TUBB | SLC6A11 1989/4885SLC6A1 1684/4885TYMP 466/4885 |
| US-20060204990-A1 | Compounds and methods for fluorescent labeling | GLB1, HLCS, PFAS | SLC6A11 1325/4885SLC6A1 1057/4885TYMP 238/4885 |
| US-20050277144-A1 | Compounds and methods for fluorescent labeling | HLCS, GLB1, TUBB | SLC6A11 1989/4885SLC6A1 1684/4885TYMP 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.